D.E. Shaw & Co
TCRR

D.E. Shaw & Co’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

D.E. Shaw & Co’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-155,495
Closed -$280K – 5303
2022
Q3 		$280K Sell
155,495
-423,392
-73% -$1.23M ﹤0.01% 4330
2022
Q2 		$1.68M Sell
578,887
-223,620
-28% -$552K ﹤0.01% 3216
2022
Q1 		$2.21M Buy
802,507
+358,750
+81% +$1.13M ﹤0.01% 3195
2021
Q4 		$2.07M Buy
+443,757
New +$2.77M ﹤0.01% 3325
2021
Q3 		– Sell
-55,350
Closed -$908K – 5377
2021
Q2 		$908K Sell
55,350
-33,040
-37% -$667K ﹤0.01% 3620
2021
Q1 		$1.95M Buy
+88,390
New +$2.41M ﹤0.01% 2612

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

D.E. Shaw & Co's TCRR Position: Q4 2022 in Review

D.E. Shaw & Co sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2022, closing a stake of 155,495 shares — an estimated $280K sold.

D.E. Shaw & Co first reported a position in TCRR in Q1 2021 and held it in 6 quarters. The position peaked at $2.21M in Q1 2022. 63 funds tracked by Wall St. Rank hold TCRR as of Q4 2022.

  • D.E. Shaw & Co reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 155,495 TCR2 Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $280K.
  • D.E. Shaw & Co first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 6 quarters.
  • D.E. Shaw & Co's TCR2 Therapeutics Inc. Common Stock position peaked at $2.21M in Q1 2022.
  • 63 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.